Compare CUE & INUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Inuvo Inc develops and sells information technology solutions for marketing. It develops technology to deliver content and targeted advertisements over the internet. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.